Physician profile
Allen H Unger
NPI 1225095946
$18,669.17
in general payments reported to CMS, 2019-2025
48 companies · $2,783 in 2025
The $2,783 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,227 · 2020: $1,271 · 2021: $2,350 · 2022: $2,362 · 2023: $2,908 · 2024: $3,766 · 2025: $2,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,438 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,437.53 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,777.19 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,706.39 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $1,251.58 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,219.22 | 2021-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $1,150.50 | 2019-2025 | |
| Amgen INC. | $1,109.95 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $1,012.82 | 2020-2025 | Nexletol |
| Qol Medical, LLC | $977.06 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $884.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $842.69 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Lilly USA, LLC | $647.34 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $639.33 | 2019-2022 | |
| Lundbeck LLC | $619.83 | 2023-2025 | Vyepti |
| Phathom Pharmaceuticals, INC. | $384.07 | 2024 | Voquezna |
| Abbvie INC. | $342.78 | 2022-2025 | Linzess, Qulipta, Viberzi |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Unger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.